Schizopherenia

Download as docx, pdf, or txt
Download as docx, pdf, or txt
You are on page 1of 3

Schizophrenia is a severe mental disorder characterized by positive symptoms such as delusions

and hallucinations, negative symptoms including amotivation and social withdrawal, and

cognitive symptoms such as difficulties with working memory and cognitive flexibility. The

disorder results in significant healthcare costs and is linked to a reduced life expectancy (Boland

et al., 2022).

It is crucial to diagnose schizophrenia accurately. The American Psychiatric Association (APA,

2022) has established specific diagnostic criteria. Two or more symptoms should be present for a

significant amount of time, for one month. These include Delusions, Hallucinations,

Disorganized speech (e.g., frequent derailment or incoherence), grossly disorganized or catatonic

behavior, Negative symptoms (e.g., diminished emotional expression or avolition), and

Continuous signs of the disturbance persist for at least six months.

For a significant portion of time since the onset of the disturbance, the level of functioning in

one or more major areas, such as work, interpersonal relations, or self-care, has been markedly

below the level achieved prior to the onset (or, when the onset is in childhood or adolescence,

there has been a failure to achieve the expected level of interpersonal, academic, or occupational

functioning).

Schizoaffective disorder and depressive or bipolar disorder with psychotic features have been

ruled out.

The disturbance is not attributable to the physiological effects of a substance (e.g., a

drug of abuse, a medication) or another medical condition.

If there is a history of autism spectrum disorder or a communication disorder


of childhood onset, the additional diagnosis of schizophrenia is made only if

prominent delusions or hallucinations, in addition to the other required symptoms of

schizophrenia, are also present for at least one month (or less if successfully treated).

Treatment

The use of antipsychotic medications is vital for managing acute psychotic episodes, as it

significantly alleviates symptoms in 81% of individuals experiencing first-episode schizophrenia

and 51% of those grappling with chronic schizophrenia. Treating the negative symptoms of

schizophrenia with pharmaceuticals alone is challenging. Psychosocial interventions in

combination with antipsychotics can address defeatist beliefs, negative expectations, and asocial

preferences. Incorporating general behavioral and skill-based interventions such as social skills

training and cognitive remediation therapy is crucial. Cognitive behavioral therapy (CBT) has

shown moderate positive effects in reducing apathy and improving motivation as a complement

to antipsychotic treatment (Correll & Schooler, 2020).

Prognosis

Patients diagnosed with schizophrenia often face a more challenging outlook compared to those

with other psychotic disorders. Our study underscores the critical importance of providing

ongoing supportive care and treatment for this complex mental condition. The findings challenge

the misconception that schizophrenia always leads to a decline in mental health. It is possible to

recover from schizophrenia. However, schizophrenia is still a severe and intricate mental

disorder, with a slight improvement in prognosis despite over 100 years of research and attempts

to enhance treatment (Molstrom et al., 2022).


References

American Psychiatric Association. (2022). Schizophrenia spectrum and other psychotic

disorders. (2022). Diagnostic and Statistical Manual of Mental Disorders.

https://doi.org/10.1176/appi.books.9780890425787.x02_schizophrenia_spectrum

Boland, R. J., Verduin, M. L., Ruiz, P. (2022). Kaplan & Sadock’s Synopsis of Psychiatry. (12th

ed.) Wolters Kluwer.

Correll, C. U., & Schooler, N. R. (2020). Negative symptoms in schizophrenia: A review and

Clinical Guide for recognition, assessment, and treatment. Neuropsychiatric Disease and

Treatment, Volume 16, 519–534. https://doi.org/10.2147/ndt.s225643

Molstrom, I.-M., Nordgaard, J., Urfer-Parnas, A., Handest, R., Berge, J., & Henriksen, M. G.

(2022). The prognosis of schizophrenia: A systematic review and meta-analysis with meta-

regression of 20-year follow-up studies. Schizophrenia Research, 250, 152–163.

https://doi.org/10.1016/j.schres.2022.11.010.

You might also like